Miao Zhihua, Mu Tianhao, Liu Longying, Rao Jingjie, Jin Min, Wang Zhizheng, Wang Hui, Lu Chao, Gong Xiaolin, Zheng Dongcai, Zheng Daoming, Li Xin, Li Yingmei, Chen Shifu, Shu Xinhua
Shangrao Guangxin Traditional Chinese Medicine Hospital, Shangrao, China.
HaploX Biotechnology, Shenzhen, China.
Front Oncol. 2020 Oct 23;10:561341. doi: 10.3389/fonc.2020.561341. eCollection 2020.
Precision medicine has been getting more attention in lung cancer treatment. Here, we report an unusual case of a 71-year-old Chinese male patient with poorly differentiated lung adenocarcinoma with lymph node metastasis. A 5 years' treatment history of this patient is reported. By serial genetic tests of circulating tumor DNA (ctDNA) from peripheral blood and sediment cell genomic DNA (PE-sDNA) from pleural effusion, a novel chronological combination treatment of icotinib, osimertinib, and crizotinib was adopted for the present genetic mutations, including exon 19 deletion, p.T790M, and amplification.
精准医学在肺癌治疗中越来越受到关注。在此,我们报告一例不同寻常的病例,一名71岁中国男性患者,患有低分化肺腺癌并伴有淋巴结转移。报告了该患者5年的治疗史。通过对来自外周血的循环肿瘤DNA(ctDNA)和来自胸腔积液的沉淀细胞基因组DNA(PE-sDNA)进行系列基因检测,针对包括外显子19缺失、p.T790M和扩增在内的当前基因突变,采用了埃克替尼、奥希替尼和克唑替尼的新型序贯联合治疗。